Associated Genetic Biomarkers
ERBB2 L755S is present in 0.17% of AACR GENIE cases, with breast invasive lobular carcinoma, breast invasive ductal carcinoma, invasive breast carcinoma, mixed lobular and ductal breast carcinoma, and bladder urothelial carcinoma having the greatest prevalence .
ERBB2 L755S is a predictive biomarker for use of ado-trastuzumab emtansine in patients.
Of the therapies with ERBB2 L755S as a predictive biomarker, 1 has NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against ERBB2 L755S or its related pathways .
Ado-Trastuzumab Emtansine +
Non-Small Cell Lung Carcinoma -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Metastatic (NCCN)|
|Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN.|
ERBB2 L755S serves as an inclusion eligibility criterion in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 L755S as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).
Trials with ERBB2 L755S in the inclusion eligibility criteria most commonly target breast carcinoma, lung carcinoma, malignant solid tumor, and non-small cell lung carcinoma .
Bdtx-189, ado-trastuzumab emtansine, docetaxel, neratinib, and pertuzumab are the most frequent therapies in trials with ERBB2 L755S as an inclusion criteria .
Significance of ERBB2 L755S in Diseases
Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 3.97% of non-small cell lung carcinoma patients .
ERBB2 L755S is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 L755S and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Ado-trastuzumab emtansine has evidence of efficacy in patients with ERBB2 L755S in non-small cell lung carcinoma .
Malignant Solid Tumor +
ERBB2 is altered in 5.44% of malignant solid tumor patients with ERBB2 L755S present in 0.16% of all malignant solid tumor patients .
ERBB2 L755S is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 L755S and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) .
Breast Carcinoma +
ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 L755S present in 0.76% of all breast carcinoma patients .
ERBB2 L755S is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 L755S and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Lung Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.